<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Patients with <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (AF) and atrial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> have an increased risk for <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, there is little knowledge about the long-term fate of atrial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> and the incidence of <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> in patients under oral anticoagulation </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Consecutive patients with persistent or permanent AF and left atrial (LA) <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> were included in the study </plain></SENT>
<SENT sid="3" pm="."><plain>We performed serial and prospective transesophageal echocardiography, cranial magnetic resonance imaging, and clinical examinations during a period of 3 years </plain></SENT>
<SENT sid="4" pm="."><plain>Oral anticoagulation was continued or initiated in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="5" pm="."><plain>A target INR of 2.5 was intended in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Forty-three patients with LA <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> and persistent or permanent AF were included </plain></SENT>
<SENT sid="7" pm="."><plain>During the follow-up period 31(72%) of the <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> disappeared </plain></SENT>
<SENT sid="8" pm="."><plain>Patients with disappearance of <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> had significantly smaller <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> (P &lt; 0.01), a lower echogenicity of <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> (P &lt; 0.01), and a lower LA volume (P = 0.02) </plain></SENT>
<SENT sid="9" pm="."><plain>Twenty-two (51%) patients suffered from <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> and/or <z:hpo ids='HP_0011420'>death</z:hpo> during the observation period </plain></SENT>
<SENT sid="10" pm="."><plain>Five patients died due to embolic events </plain></SENT>
<SENT sid="11" pm="."><plain>The only independent predictors of <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> were an elevated peak emptying velocity of the LA appendage (P &lt; 0.001) and a history of previous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> (P &lt; 0.01) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: Patients with persistent or permanent AF and atrial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> have a high long-term risk of <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> and/or <z:hpo ids='HP_0011420'>death</z:hpo> (51%) even despite the oral anticoagulation therapy </plain></SENT>
<SENT sid="13" pm="."><plain><z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">Thrombus</z:e> size may predict <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> resolution under continued anticoagulation </plain></SENT>
</text></document>